SCHEMBL18220211

SCHEMBL18220211

CCN(CC)c1ccc2cc(-c3ccc(/C(C)=C(\C#N)C(=O)NCCOC)n3C)ccc2c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.35
ALDH1A1 P00352 5/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
HPGD P15428 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MITF O75030 1/20 0.35
MAPK1 P28482 1/20 0.35
MDM2 Q00987 1/20 0.35
EGLN2 Q96KS0 1/20 0.35
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33
HTT P42858 2/20 0.33
ESRRG P62508 1/20 0.33
MAPT P10636 5/20 0.32
KDM4E B2RXH2 4/20 0.32
USP2 O75604 1/20 0.32
CYP1A2 P05177 1/20 0.32
MAOB P27338 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18220203 0.93 LMNA (0.34) LMNAALDH1A1MEN1KMT2AHPGD
SCHEMBL18220199 0.91 ALDH1A1 (0.36) LMNAALDH1A1MEN1KMT2AHPGD
SCHEMBL18220223 0.85 CTSS (0.34) ALDH1A1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL21226386 0.85 SCN9A (0.36) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL17120846 0.84 CTSS (0.33) MEN1KMT2ACTSSCTSKESRRG
SCHEMBL17120811 0.83 MAPT (0.38) ALDH1A1MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL18220205 0.82 KDM4E (0.32) ALDH1A1MEN1KMT2ACTSSCTSK
SCHEMBL19293428 0.82 ESRRG (0.43) LMNAALDH1A1MEN1KMT2AHPGD
SCHEMBL18220206 0.82 APP (0.44) ALDH1A1MEN1KMT2AEGLN2CTSS
SCHEMBL18220197 0.82 APP (0.42) LMNAALDH1A1MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-20210369873-A1 COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY Amydis, Inc. 2021-12-02 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 LMNA 1263/4885ALDH1A1 4151/4885MEN1 2997/4885
US-20210369873-A1 COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY S100B, FABP7, CRYAB LMNA 270/4885ALDH1A1 4102/4885MEN1 1595/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 LMNA 1263/4885ALDH1A1 4151/4885MEN1 2997/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA LMNA 1283/4885ALDH1A1 4226/4885MEN1 2973/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA LMNA 1283/4885ALDH1A1 4226/4885MEN1 2973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.